ArticleBlood advances2026
Advancing precision therapy in pediatric acute myeloid leukemia through PDX models and mitochondrial targeting.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractIn pediatric acute myeloid leukemia (pAML) relapse/refractory (R/R) disease occurs frequently, but underlying mechanisms are unclear and effective second-line therapeutic options remain limited. Although genomic characterization has advanced targeted treatments, their clinical implementation, particularly in the pediatric field, is hindered by toxicities or resistance due to poor correlation between preclinical and clinical studies. The use of more robust preclinical models is crucial for developing effective therapies. We established 26 patient-derived xenografts (PDXs) of pAML representing 14 high-risk genetic subtypes. These PDXs faithfully recapitulated the molecular complexity and heterogeneity of primary AML, and preserved the immunophenotypic, genomic, and transcriptomic profiles. Clonal and transcriptomic dynamics were tracked from patient samples to their matched PDXs, and vulnerabilities that could be exploited as therapeutic targets were identified, facilitating the evaluation of multifaceted therapeutic strategies. We selected druggable variants and aberrantly activated pathways in KMT2A-rearranged (KMT2A-r) AML and performed an in vitro drug screening of actionable targets exploiting a predictive 3-dimensional coculture model. Promising compounds were tested in vivo in AML PDXs. Among new drugs targeting variants and pathways, we demonstrate that the combination of IACS-010759, a mitochondrial complex I inhibitor, and venetoclax, a B-cell lymphoma 2 inhibitor, reduces AML progression in KMT2A-r PDXs modeling both disease onset and relapse. The combination of venetoclax with IACS-010759 with a stromal targeting drug slowed AML progression in a resistant model. Overall, our study highlights the power of AML PDXs as a translational platform for novel targeted therapy identification. Our preclinical results testing venetoclax with IACS-010759 in KMT2A-r AML strongly support mitochondrial targeting in this genetic AML subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.